Beta Bionics, Inc. Common Stock vs. Boston Scientific Corp.
Boston Scientific Corp. (BSX) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| BBNX | BSX | |
|---|---|---|
| Market Cap | $997.87 million | $63.58 billion |
| Revenue (TTM) | — | $21.00 billion |
| Net Income (TTM) | — | $3.67 billion |
BSX leads on 1 of 1 size & scale factors.
Valuation
| BBNX | BSX | |
|---|---|---|
| P/E Ratio | — | 17.78 |
| Price / Book | 3.89 | 2.53 |
| Price / Sales | — | 3.03 |
BSX leads on 1 of 1 valuation factors.
Profitability
| BBNX | BSX | |
|---|---|---|
| Net Margin | — | 17.47% |
| Return on Equity | — | 14.57% |
BBNX and BSX split the profitability factors evenly.
Risk & Sentiment
| BBNX | BSX | |
|---|---|---|
| Short Interest | 0.47% | 0.72% |
BBNX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BBNX overview, BBNX financials, BSX overview, BSX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.